SC-57461A is a highly potent, orally bioavailable nonpeptide compound that selectively inhibits Leukotriene A4 (LTA4) hydrolase. It demonstrates strong activity with IC50 values of 2.5 nM (human), 3 nM (mouse), and 23 nM (rat) for recombinant LTA4 hydrolase.

Gboxin is a compound that disrupts oxidative phosphorylation, making it a promising therapeutic agent specifically for glioblastoma treatment.

VPC-80051 (VPC80051) is the first small molecule inhibitor of hnRNP A1 splicing activity, targets RNA-binding domain (RBD) of hnRNP A1.

RG7834 (RO 7020322) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells.

BAY-184 is the first, potent and selective acylsulfonamide-benzofuran in vivo-active KAT6A/B inhibitor with IC50 of 71 nM.

A-485 is a highly potent and selective small-molecule inhibitor targeting the catalytic activity of p300/CBP histone acetyltransferases (HATs). It demonstrates remarkable inhibitory potency, with IC50 values of 9.8 nM (p300) and 2.6 nM (CBP).

CVT-11127 functions as a potent inhibitor of stearoyl-CoA desaturase (SCD), demonstrating significant biological activity. This compound triggers apoptotic pathways and effectively halts cell cycle progression at the G1/S transition phase. Due to these mechanisms of action, CVT-11127 shows promise as a candidate for lung cancer research.

CU-CPT-8m is a nolve TLR8 inhibitor.

AGK2 is a potent and selective SIRT2 inhibitor, exhibiting an IC50 of 3.5 μM against this target. While it primarily acts on SIRT2, it also weakly inhibits SIRT1 (IC50 = 30 μM) and SIRT3 (IC50 = 91 μM), demonstrating lower potency toward these isoforms.

NS13001 is a highly selective and orally bioavailable allosteric positive modulator targeting small-conductance calcium-activated potassium (SK) channels. It exhibits potent activity, with EC50 values of 1.8 μM for SK2 and 0.14 μM for SK3, demonstrating greater potency toward SK3. Due to its pharmacological profile, NS13001 has emerged as a promising candidate for treating spinocerebellar ataxia type 2 (SCA2) and may also have therapeutic potential in other forms of cerebellar ataxia.

Imidacloprid-urea is a key breakdown product of imidacloprid, a widely applied neonicotinoid insecticide effective against pests in crops such as cereals, vegetables, tea, and cotton. As a metabolite, imidacloprid-urea may compete with imidacloprid for binding sites in soil, influencing its environmental persistence, mobility, and bioavailability. This interaction could alter the overall environmental behavior of imidacloprid, impacting its ecological fate.

Soporidine is a strigolactone (SL) antagonist and inhibitor of germination in their biological assays. It binds AtHTL and specifically interferes with SL signaling.

GNE-140 racemate consists of equal parts (R)-GNE-140 and (S)-GNE-140 enantiomers, functioning as a potent inhibitor of lactate dehydrogenase A (LDHA).

AA 41612 is a potent, synthetic melanopsin antagonist with IC50 of 15.8 nM, attenuates melanopsin photocurrent in a dose-dependent manner.

KLH45 is a selective inhibitor of DDHD2 (DDHD domain containing 2).

WWL229 is a selective, distinct Carboxylesterase Ces3 inhibitor with IC50 of 1.94 uM, but not Ces1f, ABHD6, other serine hydrolases.

NCGC00262650 demonstrates potent inhibition of the AMA1-RON2 protein interaction, effectively preventing merozoite invasion of erythrocytes.

BAY-549 (Azaindole 1) is an orally bioavailable, ATP-competitive inhibitor demonstrating potent inhibition of both ROCK isoforms, with IC50 values of 0.6 nM (ROCK-1) and 1.1 nM (ROCK-2) in human enzymes.

ML-226 is an inhibitor of α/β hydrolase domain-containing protein 11 (ABHD11) that inhibits ABHD11 in vitro and in situ.

APS-2-79 is a novel modulator of KSR-dependent MAPK signalling,KSR2,IC50=120 nM

BMS-986188 functions as a selective positive allosteric modulator for the δ-opioid receptor, demonstrating potent activity with an EC50 of 50 nM.

NCGC607 is a a small-molecule noninhibitory chaperone of glucocerebrosidase.

Metarrestin (ML246) is a specific inhibitor of perinuclear compartment (PNC), disrupts PNCs in PC3M-GFP-PTB cells with IC50 of 0.39 uM, specifically binds eEF1A2.

NSC45586 sodium is a selective inhibitor targeting the PP2C phosphatase domain within both PHLPP1 and PHLPP2 proteins. By blocking these phosphatases, it enhances AKT activation in neuronal cells.

FLTX1 is a fluorescent Tamoxifen analog capable of specifically visualizing intracellular estrogen receptor binding sites, regardless of cellular permeabilization status. This probe retains Tamoxifen's potent antiestrogenic activity in breast cancer models while lacking uterine estrogenic effects.

Negative control for GSK'963 (AOB9775). Novel highly potent and selective RIP1 inhibitor

AS1842856 is a potent and cell-permeable Foxo1 inhibitor with an IC50 of 30 nM.

TSPC is an inhibitor for GA perception by in vitro and in planta evaluations.

AF64394 is a potent, selective GPR3 inverse agonist with pIC50 of 7.3, displays >100-fold selectivity over GPR6 and GPR12.